Synkrino Biotherapeutics Patents

Patent portfolio assigned to Synkrino Biotherapeutics (verified via public assignee records). Estimated patent count: 1. Early-stage AI drug-discovery biotech (YC S18, SATIS/AIDE engine); preclinical, no commercial customers. Patent US20210251993A1 'Compositions and methods for treating diseases associated with uncontrolled inflammatory responses' assigned to Synkrino Biotherapeutics Inc (confirmed via Google Patents search). No direct competitors confidently identified.